<DOC>
	<DOCNO>NCT02014571</DOCNO>
	<brief_summary>GSK2878175 site IV NS5B non-nucleoside inhibitor ( NNI ) develop treatment chronic hepatitis C virus ( HCV ) infection . The purpose study investigate effect GSK2878175 , different dos men woman infect chronic hepatitis C virus . The study investigate much drug get blood stream long body take get rid . The study also investigate GSK2878175 important side effect . The study also measure effect GSK2878175 hepatitis C virus infection take study medication 2 day . Approximately 44 people take part study . Depending type chronic hepatitis C infection subject enrol 1 4 group randomly . Each group participate one dose session . One dose session consist GSK2878175 placebo ( sugar pill ) give per day 2 day . Group A , B , C make 8 participant per group . In group 6 participant receive GSK2878175 2 participant receive placebo . Group D make 20 participant . 15 participant receive GSK2878175 5 participant receive placebo . The treatment group dose sequence . Group A first take study medication , Group B , . The plan dose subject Group A 10 mg , Group B 30 mg , Group C 60 mg , Group D 60 mg GSK2878175 placebo . The next treatment group 's actual dose decide look result previous group . The dos may therefore high low plan depend previous group 's result . The number participant enrol next group may also change depend result previous group .</brief_summary>
	<brief_title>Study Assess Safety , Pharmacokinetics , Antiviral Activity Repeat Doses GSK2878175 Subjects With Chronic Hepatitis C .</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Antiviral Agents</mesh_term>
	<criteria>Has chronic genotype 1 ( subtypes 1a 1b ) genotype 2 genotype 3 genotype 4 ( assess VERSANT® HCV Genotype assay 2.0 ( LiPA ) ; VERSANT register trademark Siemens Healthcare company . ) HCV infection document least 1 measurement serum HCV RNA &gt; =100,000 IU/mL measure Screening COBAS® High Pure/COBAS TaqMan® HCV Test v2.0 ( COBAS TaqMan register trademark Roche Molecular Diagnostics company . ) least one following : Documented HCV serology demonstrate presence antiHCV antibody least 6 month screen ; Documented presence HCV RNA least 6 month screen ; Documented evidence fibrosis liver biopsy obtain within 3 year ( &lt; 36 calendar month ) prior Day 1visit ; FibroSure/FibroTest &gt; 0.28 &lt; =0.58 screening ( Note : subject FibroTest score &lt; =0.28 may include long meet 1 CHC criterion ) . Note : Cohorts genotype specific . Agrees IL28B genotyping . The subject able understand capable give write informed consent , include compliance requirement restriction list consent form likely complete study plan . Subjects must treatmentnaïve received prior treatment interferon , immunomodulatory agent , DAA HCV . Male female age 18 60 year age , inclusive , time signing informed consent . A female subject eligible participate : Nonchildbearing potential define premenopausal female document tubal ligation hysterectomy [ definition , `` document '' refers outcome investigator's/designee 's review subject 's medical history study eligibility , obtain via verbal interview subject subject 's medical record ] ; postmenopausal define 12 month spontaneous amenorrhea [ questionable case blood sample simultaneous follicle stimulate hormone ( FSH ) &gt; 40 MIU/ml estradiol &lt; 40 pg/ml ( &lt; 147 pmol/L ) confirmatory ] . Childbearing potential negative pregnancy test determine serum hCG test ( Screening Day 1 ) urine hCG test Day 1 : Agrees use one contraception method appropriate period time ( determined product label investigator ) prior start dose sufficiently minimize risk pregnancy point . Female subject must agree use contraception 28 day post last dose . OR samesex partner , prefer usual lifestyle . Male subject female partner childbearing potential must agree use one contraception method . This criterion must follow time first dose study medication follow visit ( 14 day post last dose ) . Body weight &gt; 50kg ( 110 lb ) men &gt; 45kg ( 99 lb ) woman body mass index ( BMI ) 18.535 kg/m^2 inclusive allow . The subject 's systolic blood pressure inside range 90140 mmHg , diastolic blood pressure inside range 4590 mmHg . Heart rate inside range 50100 bpm female subject 45100 bpm male subject . Is otherwise healthy determine medical history , physical examination , ECG finding , clinical laboratory measurement perform Screening . Aspartate transaminase ( AST ) , Alanine transaminase ( ALT ) , Alkaline Phosphatase ( ALP ) &lt; 2X Upper Limit Normal ( ULN ) . Total bilirubin &lt; 2X ULN ( except subject Gilbert 's syndrome ) . Absolute neutrophils count &gt; =1000/mm^3 . Albumin &gt; =3.5 g/dL . Platelet count &gt; =140000/mm^3 . Hemoglobin : &gt; =11 g/dL female subject &gt; =12 g/dL male subject Note : subject baseline hemoglobin low limit normal , attention pay correctable cause anemia iron , folate , B12 deficiency . All hematology clinical chemistry ; clinically significant abnormality laboratory value preclude treatment . Based single average QTc value triplicate ECGs obtain brief recording period : QTcF &lt; 450 msec ; QTcF &lt; 480 msec subject Bundle Branch Block . History illness , opinion investigator , might confound result study pose additional risk administer study drug ( ) subject . Family history prolong QT syndrome ( Torsade de Pointes ) sudden cardiac death ; firstdegree relative myocardial infarction premature age ( &lt; =45 year male relative ; &lt; =55 year female relative ) . History clinical evidence hypertension , significant unstable cardiac disease ( e.g. , prolonged QT syndrome [ torsade de point ] , angina , congestive heart failure , myocardial infarction , diastolic dysfunction , significant arrhythmia , coronary heart disease , and/or clinically significant ECG abnormality ) . Evidence cirrhosis , determine 1 following : FibroSure/FibroTest score &gt; 0.58 ; Liver biopsy fibrosis stage indicative cirrhosis classify local pathologist ( define Knodell &gt; 3 , Metavir &gt; 2 , Ishak &gt; 4 , Batts Ludwig &gt; 2 ) . Both incomplete transition cirrhosis ( e.g. , Metavir score 3 ) consider cirrhosis ; History ascites , hepatic encephalopathy , esophagogastric varix . Active malignant disease history malignant disease within 5 year screen , exception successfully treat basal cell carcinoma , squamous cell cancer skin , carcinoma cervix situ . Any cause significant liver disease addition hepatitis C , may include limited malignancy hepatic involvement , hepatitis B , druginduced alcoholrelated liver disease , autoimmune hepatitis , hemochromatosis , Wilson 's disease , nonalcoholic steatohepatitis , primary biliary cirrhosis . Estimated creatinine clearance ≤50 mL/min use CockcroftGault equation screening . A medical condition require frequent prolong use systemic corticosteroid immunosuppressive drug ( e.g. , severe asthma ; severe arthritis autoimmune condition ; organ transplantation ; acute adrenal insufficiency ) . History regular alcohol consumption within 1 month study define : average weekly intake &gt; 14 drink male &gt; 7 drink female . One drink equivalent 12 g alcohol : 12 ounce ( 360 mL ) beer , 5 ounce ( 150 mL ) wine 1.5 ounce ( 45 mL ) 80 proof distil spirit . Unwilling abstain alcohol 48 hour prior start dose collection final pharmacokinetic sample treatment period . History sensitivity heparin heparininduced thrombocytopenia . History sensitivity study medication , component thereof history drug allergy contraindicate participation . Use prescription nonprescription drug , include vitamin , herbal dietary supplement ( include St John 's Wort ) within 7 day ( 14 day drug potential enzyme inducer ) 5 halflives ( whichever longer ) prior first dose study medication . Consumption red wine , Seville oranges , grapefruit grapefruit juice , pummelo , satsuma , ugli , tangerine , tangelo , exotic citrus fruit , grapefruit hybrid fruit juices 5 day prior first dose study medication . A positive prestudy Hepatitis B surface antigen result within 3 month screen . A positive test HIV antibody . A positive prestudy drug/alcohol screen . Unwilling refrain use illicit drug adhere protocolstated restriction participate study . Holter monitoring show one following : Any symptomatic arrhythmia ( except isolate extra systole ) . Sustained cardiac arrhythmia ( atrial fibrillation flutter , SVT ( &gt; 10 consecutive beat ) . Sinus tachycardia ( supraventricular tachycardia ) great 150 bpm . Nonsustained sustain ventricular tachycardia ( define &gt; 3 consecutive ventricular ectopic beat ) . Any conduction abnormality ( include specific leave right complete bundle branch block , AV block [ 2nd degree high awake subject ] , WPW syndrome , preexcitation syndrome ) . Symptomatic sinus pause sinus pause &gt; 3 second unless subject straining , vomit , type hypervagal response . 300 supraventricular ectopic beat 24 hour . 250 ventricular ectopic beat 24 hour . Ischemia , diagnose sequence ECG change include flat slop STsegment depression &gt; 0.1 mV , gradual onset offset last minimum period 1 minute . Each episode ischemia must separate minimum duration least 1 minute , ST segment return back baseline ( 1x1x1 rule ) . Unable use spirometry equipment correctly . Abnormal spirometry result : FEV1 le 80 % predict value FEV1/FVC le 70 % History active diagnosis pulmonary disease asthma , emphysema , chronic obstructive pulmonary disease ( COPD ) interstitial lung disease . History active diagnosis thyroid disease . Any condition possibly affect drug absorption ( e.g. , gastrectomy significant gastrointestinal tract surgery , gastroenterostomy , small bowel resection , active enterostomy ) . Lactating female . Where participation study would result donation blood blood product excess 550 mL within 56 day period . The subject participate clinical trial receive investigational product within following time period prior first dose day current study : 30 day , 5 halflives twice duration biological effect investigational product ( whichever longer ) . Exposure four new chemical entity within 12 month prior first dose day .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>Safety</keyword>
	<keyword>NS5B</keyword>
	<keyword>pharmacokinetics ( PK )</keyword>
	<keyword>hepatitis C virus ( HCV )</keyword>
	<keyword>antiviral activity</keyword>
	<keyword>GSK2878175</keyword>
	<keyword>chronic hepatitis C ( CHC )</keyword>
</DOC>